CTOs on the Move

Teewinot Life Sciences Corp

www.tlscorp.com

 
Teewinot Life Sciences is a global biopharmaceutical company focused on the biosynthetic production of pure pharmaceutical grade cannabinoids. Teewinot has developed patent protected processes for production of pure cannabinoids by means of biocatalysis and synthetic biology. Teewinot has also developed patent protected cannabinoid formulation technology all with the goal of improving human therapies. Headquartered in Tampa, Florida, Teewinot manufactures and licenses technology to make cost-effective and pharmaceutically pure cannabinoids. We are an industry leader in support of advancing medical research and product development. Teewinot`s global technology and intellectual property represent a breakthrough in the creation and delivery of cannabinoid-based medicines.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.tlscorp.com
  • 12005 Whitmarsh Lane
    Tampa, FL USA 33626
  • Phone: 813.803.6300

Executives

Name Title Contact Details

Funding

Teewinot Life Sciences Corp raised $12.3M on 05/01/2017

Similar Companies

Roar Biomedical

Roar Biomedical is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PathoGenetix

PathoGenetix is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elco Laboratories Inc

ELCO Laboratories, Inc. is the manufacturer of Cooktop Cleaning Creme, Stainless Steel Cleaner, Gas Grate Cleaner, and other quality cleaning products.

BioComm Network

BioComm Network is a Laguna Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ignyta

Ignyta, located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Its goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. The company's present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases